Cited by 85Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Aβ1–40 but not Aβ1–42 levels in cortex correlate with apolipoprotein E ϵ4 allele dosage in sporadic Alzheimer's disease

Ishii, Kazuhiro, Tamaoka, Akira, Mizusawa, Hidehiro, Shoji, Shin-ichi, Ohtake, Toshiyuki, Fraser, Peter E, Takahashi, Hitoshi, Tsuji, Shoji +7 more·1997·Brain Research

Abstract

Apolipoprotein E (ApoE) epsilon4 allele is established to be a risk factor for the development of late-onset Alzheimer's disease (AD) which is associated with increased frequency of senile plaques and extent of amyloid angiopathy. In a recent report, we demonstrated that ApoE epsilon4 dosage correlates with an increase in A beta1-40 but not A beta1-42/43-immunoreactive plaques. In the present study, we sought to confirm this relationship at a biochemical level by using a sensitive ELISA to measure the amounts of A beta1-42/43 and A beta1-40 in cerebral cortex in 36 cases of sporadic AD. We found that dosage of ApoE epsilon4 allele correlated significantly with cortical A beta1-40 levels, while levels of A beta1-42 showed no significant association with genotype. These results parallel our immunohistochemical findings and suggest that A beta1-40 may play a key role in the pathogenesis of late-onset sporadic AD.

Integrity signals

Registry

Crossref · 10.1016/s0006-8993(96)01363-7

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several reports suggest that Aβ40 preferentially aggregates in an apoE4 gene dose-dependent manner in AD subjects.

    “Interestingly, there have been several reports suggesting that Aβ40 preferentially aggregates in an apoE4 gene dose-dependent manner in AD subjects (Gearing et al., 1996; Ishii et al., 1997; Mann et al., 1997).”

    From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Ishii et al., 1997

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ishii, K., Tamaoka, A., Mizusawa, H., Shoji, S.-I., Ohtake, T., Fraser, P. E., Takahashi, H., Tsuji, S., Gearing, M., Mizutani, T., Yamada, S., Kato, M., St.George-Hyslop, P. H., Mirra, S. S., & Mori, H.
Affiliations
  • University of Tsukuba (JP)
  • Tokyo Metropolitan Neurological Hospital (JP)
  • University of Toronto (CA)
  • Brain Research Institute, Niigata University (JP)
  • Emory University (US)
  • Tokyo Metropolitan Institute of Gerontology (JP)
  • Tokyo Institute of Psychiatry (JP)
Corresponding author
Mori, Hiroshi
Venue
Brain Research
Publisher
Elsevier BV
Published
1997-02
Volume
748
Issue
1-2
Pages
250-252
ISSN
0006-8993 (ISSN-L)
OpenAlex
W2112357968
Cited by
85
References
5
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2022: 1 · 2021: 1 · 2017: 2 · 2016: 2 · 2015: 1 · 2013: 2 · 2012: 1
FWCI
6.28
Type
journal article
Language
en
Open access
closed
Locations
  • Brain Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • Japan Society for the Promotion of Science
  • National Institute on Aging (P30AG010130, AG-10130)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, APOE ε4, APOE genotype, Aβ40, amyloid-beta 42, cerebral cortex, sporadic Alzheimer's disease, late-onset Alzheimer's disease, amyloid plaques, pathogenesis
MeSH terms
Aged, Alleles, Alzheimer Disease, Apolipoproteins E, Cerebral Cortex, Humans, Middle Aged, Peptide Fragments, Amyloid beta-Peptides, Gene Dosage, Apolipoprotein E4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review